MCID: SLP001
MIFTS: 48

Sleeping Sickness malady

Categories: Infectious diseases, Rare diseases

Aliases & Classifications for Sleeping Sickness

Aliases & Descriptions for Sleeping Sickness:

Name: Sleeping Sickness 12 51 56 3 14
African Trypanosomiasis 12 56 3 69
African Sleeping Sickness 12
Trypanosomiasis, African 42
Trypanosomiasis African 52

Characteristics:

Orphanet epidemiological data:

56
african trypanosomiasis
Inheritance: Not applicable; Age of onset: All ages;

Classifications:

Orphanet: 56  
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:10112
ICD10 33 B56 B56.9
ICD9CM 35 086.5
MeSH 42 D014353
NCIt 47 C84541
Orphanet 56 ORPHA3385
MESH via Orphanet 43 D014353
UMLS via Orphanet 70 C0041228
ICD10 via Orphanet 34 B56.0 B56.1 B56.9
UMLS 69 C0041228

Summaries for Sleeping Sickness

NINDS : 51 Encephalitis lethargica is a disease characterized by high fever, headache, double vision, delayed physical and mental response, and lethargy. In acute cases, patients may enter coma. Patients may also experience abnormal eye movements, upper body weakness, muscular pains, tremors, neck rigidity, and behavioral changes including psychosis. The cause of encephalitis lethargica is unknown. Between 1917 to 1928, an epidemic of encephalitis lethargica spread throughout the world, but no recurrence of the epidemic has since been reported. Postencephalitic Parkinson's disease may develop after a bout of encephalitis-sometimes as long as a year after the illness.

MalaCards based summary : Sleeping Sickness, also known as african trypanosomiasis, is related to trypanosomiasis, human east-african and trypanosomiasis, human west-african. An important gene associated with Sleeping Sickness is APOL1 (Apolipoprotein L1), and among its related pathways/superpathways are African trypanosomiasis and Metabolism. The drugs Clonidine and Trazodone have been mentioned in the context of this disorder. Affiliated tissues include eye, testes and brain.

CDC : 3 African Trypanosomiasis, also known as "sleeping sickness," is caused by microscopic parasites of the species Trypanosoma brucei. It is transmitted by the tsetse fly (Glossina species), which is found only in rural Africa. Although the infection is not found in the United States, historically, it has been a serious public health problem in some regions of sub-Saharan Africa. Currently, about 10,000 new cases each year are reported to the World Health organization; however, it is believed that many cases go undiagnosed and unreported. Sleeping sickness is curable with medication, but is fatal if left untreated.

Disease Ontology : 12 A trypanosomiasis that results from infection by Trypanosoma brucei and gambiense, which is transmitted by the bite of an infected tsetse fly (Glossina spp). The symptoms include fever, headache, joint pain, itching, confusion, sensory disturbances, poor coordination and sleep disturbances.

Related Diseases for Sleeping Sickness

Diseases related to Sleeping Sickness via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 37)
id Related Disease Score Top Affiliating Genes
1 trypanosomiasis, human east-african 11.0
2 trypanosomiasis, human west-african 11.0
3 trypanosomiasis 10.4
4 ureter inverted papilloma 10.1 IL10 IL6
5 colon adenocarcinoma 10.1 IL10 IL6 MDH2
6 keratomalacia 10.1 IL10 IL6 NOS2
7 myopathy, congenital, with fiber-type disproportion, x-linked 10.1 ABCB7 MDH2
8 bare lymphocyte syndrome, type i 10.1 IL10 IL6 NOS2
9 malaria 10.1
10 erythematosquamous dermatosis 10.1 IL10 NOS2 SRM
11 liver inflammatory pseudotumor 10.0 IL10 NOS2 PGD
12 detrusor sphincter dyssynergia 10.0 AMD1 IL10 IL6 NOS2
13 chagas disease 10.0
14 leishmaniasis 10.0
15 alcoholic hepatitis 10.0 IL10 IL6 TF
16 neonatal hypoxic and ischemic brain injury 10.0 APOA1 IL10 IL6
17 trichomalacia 10.0 APOA1 IL10 IL6
18 nervous system cancer 9.9 IL10 IL6 TF
19 ectodermal dysplasia bartalos type 9.9 IL10 IL6 NOS2 TF
20 choroiditis 9.9
21 cerebritis 9.9
22 encephalopathy 9.9
23 immunodeficiency due to defect in mapbp-interacting protein 9.8 IL10 IL6 NOS2 ODC1 SRM
24 membranoproliferative glomerulonephritis 9.8 IL10 IL6 TF
25 pigmentation disease 9.8 AMD1 APOL1 IL10 IL6 ODC1 TF
26 hepatitis c 9.6
27 hypogonadism 9.6
28 viral encephalitis 9.6
29 neuronitis 9.6
30 narcolepsy 9.6
31 visceral leishmaniasis 9.6
32 encephalitis 9.6
33 hepatitis c virus 9.6
34 hepatitis 9.6
35 rabies 9.6
36 diabetes mellitus, insulin-dependent, 20 9.5 APOA1 IL10 IL6 NOS2 TF
37 hyperpigmentation of eyelid 8.1 ABCB7 AMD1 APOA1 APOL1 CTPS1 GAPDH

Graphical network of the top 20 diseases related to Sleeping Sickness:



Diseases related to Sleeping Sickness

Symptoms & Phenotypes for Sleeping Sickness

Drugs & Therapeutics for Sleeping Sickness

Drugs for Sleeping Sickness (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 332)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clonidine Approved Phase 4,Phase 2 4205-90-7 2803
2
Trazodone Approved, Investigational Phase 4,Phase 2,Phase 3 19794-93-5 5533
3
Amitriptyline Approved Phase 4 50-48-6 2160
4
Cyclobenzaprine Approved Phase 4 303-53-7 2895
5
Sodium oxybate Approved Phase 4,Phase 2 502-85-2 5360545
6
Benzocaine Approved Phase 4,Phase 3,Phase 1 1994-09-7, 94-09-7 2337
7
Dexmedetomidine Approved, Vet_approved Phase 4 76631-46-4, 113775-47-6 68602 5311068 56032
8
Bupropion Approved Phase 4,Phase 3 34841-39-9, 34911-55-2 444
9
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
10
Acetazolamide Approved, Vet_approved Phase 4,Phase 1 59-66-5 1986
11
Ziprasidone Approved Phase 4 146939-27-7 60854
12
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
13
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
14
Armodafinil Approved, Investigational Phase 4,Phase 3,Phase 2 112111-43-0
15
Modafinil Approved, Investigational Phase 4,Phase 3,Phase 2 68693-11-8 4236
16
Zolpidem Approved Phase 4 82626-48-0 5732
17
Ethanol Approved Phase 4,Phase 2,Phase 3 64-17-5 702
18
Topiramate Approved Phase 4 97240-79-4 5284627
19
Infliximab Approved Phase 4 170277-31-3
20
Haloperidol Approved Phase 4,Phase 3 52-86-8 3559
21
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
22
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
23
Tetracycline Approved, Vet_approved Phase 4 60-54-8 5353990
24
Levodopa Approved Phase 4 59-92-7 6047
25
Rasagiline Approved Phase 4 136236-51-6 3052776
26
Ropinirole Approved, Investigational Phase 4,Phase 3,Phase 2 91374-20-8, 91374-21-9 5095 497540
27
Methylphenidate Approved, Investigational Phase 4,Phase 2,Phase 1 113-45-1 4158
28
Etanercept Approved, Investigational Phase 4 185243-69-0
29
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2 75614-87-8, 51-45-6 774
30
Citalopram Approved Phase 4,Phase 3 59729-33-8 2771
31
Glycerol Approved, Experimental Phase 4 56-81-5 753
32
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
33
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3 83-43-2 6741
34
Prednisolone Approved, Vet_approved Phase 4,Phase 3 50-24-8 5755
35
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
36
Metformin Approved Phase 4 657-24-9 14219 4091
37
Methazolamide Approved Phase 4 554-57-4 4100
38
Nifedipine Approved Phase 4 21829-25-4 4485
39
Tibolone Approved Phase 4 5630-53-5
40 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Phase 1
41
Melatonin Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 73-31-4 896
42
decanoic acid Experimental Phase 4,Phase 3 334-48-5 2969
43 Adrenergic Agents Phase 4,Phase 3,Phase 2
44 Adrenergic Agonists Phase 4,Phase 3,Phase 2
45 Adrenergic alpha-2 Receptor Agonists Phase 4,Phase 3,Phase 2
46 Adrenergic alpha-Agonists Phase 4,Phase 3,Phase 2
47 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
48 Antihypertensive Agents Phase 4,Phase 3,Phase 2
49 Autonomic Agents Phase 4,Phase 3,Phase 2
50 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 396)
id Name Status NCT ID Phase
1 Nasal Continuous Positive Airway Pressure (CPAP) in Chronic Fatigue and Sleep-disordered Breathing Unknown status NCT01368718 Phase 4
2 Study of Clonidine on Sleep Architecture in Children With Tourette's Syndrome (TS) and Comorbid ADHD Unknown status NCT00152750 Phase 4
3 Comparison of Quetiapine and Trazodone Treatment for Insomnia in Dually Diagnosed Veterans Unknown status NCT01662297 Phase 4
4 Cyclobenzaprine Extended Release (ER) for Fibromyalgia Unknown status NCT01041495 Phase 4
5 Sodium Oxybate in Patients With Chronic Fatigue Syndrome. Unknown status NCT01584934 Phase 4
6 Effectiveness of Blood Clot Medication With Concomitant Blood Pressure Medication Unknown status NCT00424281 Phase 4
7 Clinical Study to Assess the Tolerability, Feasibility and Effectiveness of Nifurtimox and Eflornithine (NECT) for the Treatment of Trypanosoma Brucei Gambiense Human African Trypanosomiasis (HAT) in the Meningo-encephalitic Phase Completed NCT00906880 Phase 4
8 A Pilot Study of Effect of Dexmedetomidine on Sleep and Inflammation in Critically Ill Patients Completed NCT00405847 Phase 4
9 Treating Disrupted Sleep in Individuals With Inflammatory Bowel Disease Completed NCT02162862 Phase 4
10 Treatment of Patients With the Obstructive Sleep Apnea Syndrome at Altitude Completed NCT00714740 Phase 4
11 An Investigation of Sleep Architecture in Ziprasidone-Treated Bipolar Depression Completed NCT00835107 Phase 4
12 Continuous Positive Airway Pressure and Acetazolamide to Treat Sleep Apnea Syndrome Patients at Altitude Completed NCT00928655 Phase 4
13 Erythropoietin in the Prevention of Acute Mountain Sickness Completed NCT01665781 Phase 4
14 An Investigation of the Sleep Architecture and Consequent Cognitive Changes in Olanzapine-Treated Depressed Patients Completed NCT00520507 Phase 4
15 Acetazolamide for the Prevention of High Altitude Illness: a Comparison of Dosing Completed NCT01993667 Phase 4
16 Effect of Olanzapine on Sleep Electroencephalogram (EEG) in Schizophrenia Patients Completed NCT01149577 Phase 4
17 SWS And Daytime Functioning in Chronic FatiguE Syndrome (SAFFE) Completed NCT02055898 Phase 4
18 Does Nightly Dexmedetomidine Improve Sleep and Reduce Delirium in ICU Patients? Completed NCT01791296 Phase 4
19 Modafinil for the Treatment of Fatigue in Lung Cancer V9.0 Completed NCT00829322 Phase 4
20 Efficacy and Safety Assessment of ZOlpidem (Stilnox CR) in Patients With Chronic insomNIA Completed NCT01024192 Phase 4
21 An Eight Week, Double-Blind Efficacy Study of Armodafinil Augmentation to Alleviate Fibromyalgia Fatigue Completed NCT00678691 Phase 4
22 Ramelteon for the Treatment of Insomnia and Mood Stability in Patients With Euthymic Bipolar Disorder Completed NCT00552760 Phase 4
23 Efficacy and Tolerability of Topiramate in Treatment of Bipolar Mania and Alcohol Use in Adolescents and Young Adults Completed NCT00550394 Phase 4
24 Oral Melatonin in Critically Ill High-risk Patients Completed NCT00470821 Phase 4
25 A Study of Infliximab for Treatment Resistant Major Depression Completed NCT00463580 Phase 4
26 Preventing ICU Subsyndromal Delirium Conversion to Delirium With Haloperidol Completed NCT01174290 Phase 4
27 Paliperidone Extended Release in Schizophrenia Participants With Duration of Illness Less Than 10 Years Completed NCT01362439 Phase 4
28 Paroxetine in the Treatment of Chronic Primary Insomnia Completed NCT00178048 Phase 4
29 Effects of Neupro on Cardiovascular Observations in Patients With Restless Legs Syndrome Completed NCT01455012 Phase 4
30 Mindfulness Meditation for Chronic Low Back Pain in Older Adults Completed NCT00494845 Phase 4
31 The Qure Study: Q-fever Fatigue Syndrome - Response to Treatment Completed NCT01318356 Phase 4
32 Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's Disease Completed NCT01049984 Phase 4
33 Long-term Study Of Ropinirole In Restless Legs Syndrome Completed NCT00329602 Phase 4
34 Adult Study / OROS Methylphenidate Hydrochloride (HCL) (OROS MPH) in Adults With Attention Deficit Hyperactivity Disorder (ADHD) Completed NCT00937040 Phase 4
35 Life Quality and Mental State in Patients With Breast Cancer Completed NCT01458457 Phase 4
36 Study Evaluating Etanercept for the Treatment of Moderate to Severe Psoriasis Completed NCT00663052 Phase 4
37 Oxygen Versus Medical Air for Treatment of CSA in Prader Will Syndrome Recruiting NCT03031626 Phase 4
38 Ramelteon for Treatment of Insomnia in Cirrhosis Recruiting NCT03091738 Phase 4
39 The Development of Novel Clinical Tests to Diagnose and Monitor Asthma in Preschool Children Recruiting NCT02743663 Phase 4
40 Acute Unilateral Vestibulopathy and Corticosteroid Treatment Recruiting NCT02912182 Phase 4
41 Neuroprotection With Dexmedetomidine in Patients Undergoing Elective Cardiac or Abdominal Surgery (Neuprodex) Recruiting NCT02096068 Phase 4
42 Sleep Intervention During Acute Lung Injury Active, not recruiting NCT01050699 Phase 4
43 Three New Ideas to Protect Special Forces From the Stress of High Altitude Active, not recruiting NCT02463357 Phase 4
44 Stacking Exercises Aid the Decline in FVC and Sick Time Active, not recruiting NCT01999075 Phase 4
45 Melatonin for Delirium Prophylaxis Not yet recruiting NCT02282241 Phase 4
46 Use of Xyrem to Improve Sleep in Chronic Fatigue Syndrome Terminated NCT00498485 Phase 4
47 Investigation of Tibolone and Escitalopram in Perimenopausal Depression Terminated NCT01368068 Phase 4
48 Investigating the Safety of Post-surgical Analgesics in Children With Obstructive Sleep Apnea Unknown status NCT01680939 Phase 3
49 The Efficacy of the Caregiver Psychoeducational Consultation Program Unknown status NCT01001884 Phase 2, Phase 3
50 Happy Nurse Project: Lifestyle Interventions to Maintain Healthy Mental State in Hospital Nurses Unknown status NCT02151162 Phase 3

Search NIH Clinical Center for Sleeping Sickness

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: trypanosomiasis, african

Genetic Tests for Sleeping Sickness

Anatomical Context for Sleeping Sickness

MalaCards organs/tissues related to Sleeping Sickness:

39
Eye, Testes, Brain, Heart, T Cells, Salivary Gland, Pituitary

Publications for Sleeping Sickness

Articles related to Sleeping Sickness:

(show top 50) (show all 553)
id Title Authors Year
1
Predicting the Impact of Intervention Strategies for Sleeping Sickness in Two High-Endemicity Health Zones of the Democratic Republic of Congo. ( 28056016 )
2017
2
Elimination of sleeping sickness in Uganda could be jeopardised by conflict in South Sudan. ( 27955775 )
2017
3
Efficacy and Safety of Pafuramidine versus Pentamidine Maleate for Treatment of First Stage Sleeping Sickness in a Randomized, Comparator-Controlled, International Phase 3 Clinical Trial. ( 26882015 )
2016
4
Carbohydrate-Binding Non-Peptidic Pradimicins for the Treatment of Acute Sleeping Sickness in Murine Models. ( 27662652 )
2016
5
A targeted door-to-door strategy for sleeping sickness detection in low-prevalence settings in CA'te d'Ivoire. ( 27849517 )
2016
6
Xenomonitoring of sleeping sickness transmission in Campo (Cameroon). ( 27071554 )
2016
7
Transmission Dynamics of Rhodesian Sleeping Sickness at the Interface of Wildlife and Livestock Areas. ( 27262917 )
2016
8
Survey on Trypanosoma spp. infection of dogs in Gabon and its epidemiological implications for sleeping sickness. ( 26947985 )
2016
9
Efficacy, Safety, and Dose of Pafuramidine, a New Oral Drug for Treatment of First Stage Sleeping Sickness, in a Phase 2a Clinical Study and Phase 2b Randomized Clinical Studies. ( 26881924 )
2016
10
Tsetse Control and the Elimination of Gambian Sleeping Sickness. ( 27128795 )
2016
11
Trypanosoma brucei Invasion and T-Cell Infiltration of the Brain Parenchyma in Experimental Sleeping Sickness: Timing and Correlation with Functional Changes. ( 28002454 )
2016
12
Simulating the elimination of sleeping sickness with an agent-based model. ( 28008825 )
2016
13
Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness. ( 27501246 )
2016
14
Analysis of a model of gambiense sleeping sickness in humans and cattle. ( 27296784 )
2016
15
Identification of "Preferred" Human Kinase Inhibitors for Sleeping Sickness Lead Discovery. Are Some Kinases Better than Others for Inhibitor Repurposing? ( 26998514 )
2016
16
Whole genome sequencing shows sleeping sickness relapse is due to parasite regrowth and not reinfection. ( 26834831 )
2016
17
Targeting the HSP60/10 chaperonin systems of Trypanosoma brucei as a strategy for treating African sleeping sickness. ( 27720295 )
2016
18
Spatial distribution and trypanosome infection of tsetse flies in the sleeping sickness focus of Zimbabwe in Hurungwe District. ( 27884172 )
2016
19
Global Profiling and Inhibition of Protein Lipidation in Vector and Host Stages of the Sleeping Sickness Parasite Trypanosoma brucei. ( 27331140 )
2016
20
Novel Financing Model for Neglected Tropical Diseases: Development Impact Bonds Applied to Sleeping Sickness and Rabies Control. ( 27855156 )
2016
21
Silent Human Trypanosoma brucei gambiense Infections around the Old Gboko Sleeping Sickness Focus in Nigeria. ( 26941995 )
2016
22
African sleeping sickness. ( 27723399 )
2016
23
The role of cytokines in the pathogenesis and staging of Trypanosoma brucei rhodesiense sleeping sickness. ( 26807135 )
2016
24
Tsetse Control and Gambian Sleeping Sickness; Implications for Control Strategy. ( 26267814 )
2015
25
Evaluation of trypanocidal activity of combinations of anti-sleeping sickness drugs with cysteine protease inhibitors. ( 25662707 )
2015
26
Evaluating long-term effectiveness of sleeping sickness control measures in Guinea. ( 26490037 )
2015
27
Comparative analysis of cerebrospinal fluid from the meningo-encephalitic stage of T. b. gambiense and rhodesiense sleeping sickness patients using TMT quantitative proteomics. ( 26306311 )
2015
28
Reducing Human-Tsetse Contact Significantly Enhances the Efficacy of Sleeping Sickness Active Screening Campaigns: A Promising Result in the Context of Elimination. ( 26267667 )
2015
29
Alterations of orexinergic and melanin-concentrating hormone neurons in experimental sleeping sickness. ( 25595977 )
2015
30
Sleeping sickness and its relationship with development and biodiversity conservation in the Luangwa Valley, Zambia. ( 25879414 )
2015
31
Enantiospecific reassessment of the pharmacokinetics and pharmacodynamics of oral eflornithine against late-stage Trypanosoma brucei gambiense sleeping sickness. ( 25512417 )
2015
32
Accuracy of individual rapid tests for serodiagnosis of gambiense sleeping sickness in West Africa. ( 25642701 )
2015
33
Genetic diversity and population structure of Trypanosoma brucei in Uganda: implications for the epidemiology of sleeping sickness and Nagana. ( 25695634 )
2015
34
Challenges facing the elimination of sleeping sickness in west and central Africa: sustainable control of animal trypanosomiasis as an indispensable approach to achieve the goal. ( 26671582 )
2015
35
Deadly Flies, Poor Profits and Veterinary Pharmaceuticals: Sustaining the Control of Sleeping Sickness in Uganda. ( 26457971 )
2015
36
Clinical profiles, disease outcome and co-morbidities among T. b. rhodesiense sleeping sickness patients in Uganda. ( 25719539 )
2015
37
Interleukin (IL)-6 and IL-10 Are Up Regulated in Late Stage Trypanosoma brucei rhodesiense Sleeping Sickness. ( 26090964 )
2015
38
In silico drug re-purposing against African sleeping sickness using GlcNAc-PI de-N-acetylase as an experimental target. ( 26476127 )
2015
39
Trypanosome infection rates in tsetse flies in the "silent" sleeping sickness focus of Bafia in the Centre Region in Cameroon. ( 26458386 )
2015
40
Ecotype evolution in Glossina palpalis subspecies, major vectors of sleeping sickness. ( 25775377 )
2015
41
From health advice to taboo: community perspectives on the treatment of sleeping sickness in the democratic republic of congo, a qualitative study. ( 25856578 )
2015
42
Population genetics of Trypanosoma brucei gambiense in sleeping sickness patients with treatment failures in the focus of Mbuji-Mayi, Democratic Republic of the Congo. ( 25535944 )
2015
43
Baited-boats: an innovative way to control riverine tsetse, vectors of sleeping sickness in West Africa. ( 25928366 )
2015
44
Costs of using "tiny targets" to control Glossina fuscipes fuscipes, a vector of gambiense sleeping sickness in Arua District of Uganda. ( 25811956 )
2015
45
Challenges towards the elimination of Human African Trypanosomiasis in the sleeping sickness focus of Campo in southern Cameroon. ( 25129168 )
2014
46
Integration of diagnosis and treatment of sleeping sickness in primary healthcare facilities in the Democratic Republic of the Congo. ( 25329353 )
2014
47
Immune trypanolysis test with blood spotted on filter paper for epidemiological surveillance of sleeping sickness. ( 24750463 )
2014
48
Sleeping sickness epidemics and colonial responses in East and Central Africa, 1900-1940. ( 24763309 )
2014
49
Recombinant antigens expressed in Pichia pastoris for the diagnosis of sleeping sickness caused by Trypanosoma brucei gambiense. ( 25032684 )
2014
50
Public health and tropical modernity: the combat against sleeping sickness in Portuguese Guinea, 1945-1974. ( 25055331 )
2014

Variations for Sleeping Sickness

Expression for Sleeping Sickness

Search GEO for disease gene expression data for Sleeping Sickness.

Pathways for Sleeping Sickness

Pathways related to Sleeping Sickness according to KEGG:

37
id Name Kegg Source Accession
1 African trypanosomiasis hsa05143

GO Terms for Sleeping Sickness

Cellular components related to Sleeping Sickness according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 secretory granule lumen GO:0034774 9.33 APOA1 HSPA8 TF
2 high-density lipoprotein particle GO:0034364 9.32 APOA1 APOL1
3 very-low-density lipoprotein particle GO:0034361 9.26 APOA1 APOL1
4 endoplasmic reticulum lumen GO:0005788 9.26 APOA1 APOL1 IL6 TF
5 blood microparticle GO:0072562 8.92 APOA1 APOL1 HSPA8 TF

Biological processes related to Sleeping Sickness according to GeneCards Suite gene sharing:

(show all 11)
id Name GO ID Score Top Affiliating Genes
1 post-translational protein modification GO:0043687 9.78 APOA1 APOL1 IL6 TF
2 response to drug GO:0042493 9.73 APOA1 CTPS1 IL10 IL6
3 cellular response to lipopolysaccharide GO:0071222 9.63 IL10 IL6 NOS2
4 cellular protein metabolic process GO:0044267 9.62 APOA1 APOL1 IL6 TF
5 defense response to protozoan GO:0042832 9.49 IL10 IL6
6 cellular response to hepatocyte growth factor stimulus GO:0035729 9.4 IL10 IL6
7 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.37 APOA1 IL10
8 negative regulation of cytokine secretion involved in immune response GO:0002740 9.26 APOA1 IL10
9 spermidine biosynthetic process GO:0008295 9.16 AMD1 SRM
10 polyamine biosynthetic process GO:0006596 9.13 AMD1 ODC1 SRM
11 polyamine metabolic process GO:0006595 8.8 AMD1 ODC1 SRM

Sources for Sleeping Sickness

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....